$664.52
Price
$69.7B
Market Cap
16.2
P/E Ratio
12.4
Forward P/E
$40.93
EPS (TTM)
0.57%
Dividend Yield
$8.8B
Cash
$2.7B
Total Debt
103M
Shares Out
$541.00
$821.11
52-Week Range
Institutional Ownership of REGENERON PHARMACEUTICALS
|
Fund / Manager
Click to search
|
Shares | Value | % of Portfolio | Cost Basis | Est. Return |
|---|---|---|---|---|---|
|
Sound Shore Management|Harry Burn
|
151.0K | $117M | $563.80 | +34.00% | |
|
Longleaf Partners|Mason Hawkins
|
130.7K | $101M | $651.95 | +12.44% |
Trading Activity for REGENERON PHARMACEUTICALS
|
Fund / Manager
Click to search
|
Action | Change | Shares After | Value | Price |
|---|---|---|---|---|---|
| 2026-Q1 | |||||
| SELL | -14.2% | 151.0K | $117M | $764.08 | |
| SELL | -21.2% | 130.7K | $101M | $764.08 | |
| 2025-Q4 | |||||
| BUY | +52.9% | 175.9K | $136M | $692.58 | |
| BUY | +14.7% | 165.8K | $128M | $692.58 | |
| 2025-Q3 | |||||
| BUY | +18.9% | 4.6M | $2.6B | $563.80 | |
| SELL | EXIT | — | — | $563.80 | |
| SELL | -9.9% | 144.6K | $81M | $563.80 | |
| BUY | NEW | 115.0K | $65M | $563.80 | |
| 2025-Q2 | |||||
| BUY | +64.6% | 3.8M | $2.0B | $563.16 | |
| BUY | NEW | 215.0K | $113M | $563.16 | |
| BUY | +39.8% | 160.6K | $84M | $563.16 | |
| SELL | EXIT | — | — | $563.16 | |
| 2025-Q1 | |||||
| BUY | +0.1% | 2.3M | $1.5B | $687.27 | |
| BUY | NEW | 114.9K | $73M | $687.27 | |
| BUY | NEW | 97.7K | $62M | $687.27 | |
| 2024-Q4 | |||||
| BUY | +0.4% | 2.3M | $1.7B | $804.33 | |
| SELL | EXIT | — | — | $804.33 | |
| 2024-Q3 | |||||
| SELL | -0.2% | 2.3M | $2.4B | $1100.05 | |
| BUY | NEW | 49.9K | $52M | $1100.05 | |
| 2024-Q2 | |||||
| SELL | -1.9% | 2.3M | $2.4B | $969.97 | |
| 2024-Q1 | |||||
| SELL | -0.3% | 2.4M | $2.3B | $954.58 | |
| 2023-Q4 | |||||
| SELL | -0.2% | 2.4M | $2.1B | $822.79 | |
| 2023-Q3 | |||||
| SELL | -0.9% | 2.4M | $2.0B | $806.95 | |
| 2023-Q2 | |||||
| BUY | +0.4% | 2.4M | $1.7B | $767.35 | |
| 2023-Q1 | |||||
| BUY | +7.3% | 2.4M | $2.0B | $751.20 | |
| SELL | EXIT | — | — | $751.20 | |
| 2022-Q4 | |||||
| SELL | -2.8% | 2.2M | $1.6B | $737.15 | |
| SELL | -62.0% | 30.5K | $22M | $737.15 | |
| SELL | EXIT | — | — | $737.15 | |
| 2022-Q3 | |||||
| BUY | +0.9% | 2.3M | $1.6B | $610.09 | |
| SELL | -29.0% | 794 | $547000 | $610.09 | |
| 2022-Q2 | |||||
| BUY | +1.3% | 2.3M | $1.3B | $659.11 | |
| SELL | EXIT | — | — | $659.11 | |
| BUY | +21.1% | 1.1K | $661000 | $659.11 | |
| 2022-Q1 | |||||
| BUY | +701.5% | 2.2M | $1.6B | $621.27 | |
| BUY | +1.3% | 80.3K | $56M | $621.27 | |
| SELL | -28.6% | 1.4K | $966000 | $621.27 | |
| BUY | +2.2% | 924 | $645000 | $621.27 | |
| 2021-Q4 | |||||
| BUY | NEW | 279.1K | $176M | $630.59 | |
| BUY | +6.7% | 79.3K | $50M | $630.59 | |
| SELL | -10.1% | 1.9K | $1M | $630.59 | |
| SELL | -7.5% | 904 | $571000 | $630.59 | |
| 2021-Q3 | |||||
| BUY | +11.2% | 74.3K | $45M | $614.98 | |
| BUY | NEW | 2.2K | $1M | $614.98 | |
| SELL | -12.3% | 977 | $591000 | $614.98 | |
| 2021-Q2 | |||||
| BUY | +46.8% | 66.8K | $37M | $502.92 | |
| SELL | -11.2% | 1.1K | $622000 | $502.92 | |
| 2021-Q1 | |||||
| SELL | EXIT | — | — | $482.51 | |
| BUY | NEW | 45.5K | $22M | $482.51 | |
| BUY | NEW | 1.3K | $594000 | $482.51 | |
| 2020-Q4 | |||||
| BUY | +3.4% | 2.0M | $968M | $548.58 | |
| 2020-Q3 | |||||
| BUY | +5.0% | 1.9M | $1.1B | $612.57 | |
| 2020-Q2 | |||||
| BUY | +7.2% | 1.8M | $1.2B | $568.39 | |
| 2020-Q1 | |||||
| BUY | +2.7% | 1.7M | $840M | $399.14 | |
| 2019-Q4 | |||||
| BUY | +2.1% | 1.7M | $629M | $344.24 | |
| 2019-Q3 | |||||
| BUY | +3.6% | 1.6M | $456M | $296.03 | |
| 2019-Q2 | |||||
| SELL | -1.1% | 1.6M | $496M | $315.26 | |
| 2019-Q1 | |||||
| BUY | +7.9% | 1.6M | $658M | $409.58 | |
| 2018-Q4 | |||||
| SELL | -0.2% | 1.5M | $555M | $363.94 | |
| 2018-Q3 | |||||
| BUY | +0.3% | 1.5M | $601M | $376.33 | |
| 2018-Q2 | |||||
| BUY | +4.5% | 1.5M | $512M | $312.57 | |
| 2018-Q1 | |||||
| BUY | +2.1% | 1.4M | $489M | $339.08 | |
Insider Trading for REGENERON PHARMACEUTICALS
No Insider Transactions
No Form 4 filings found for this stock in the last 2 years.